News
Sarepta may not survive its current gene therapy crisis
Digest more
Most investors don’t see the drugmaker’s executive management as credible, following the failure to disclose a patient death, ...
The FDA will request Sarepta Therapeutics stop all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, ...
On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.
Company CEO Doug Ingram said the pause was necessary for Sarepta to maintain a "productive and positive working relationship" ...
A timeline of key developments surrounding Sarepta Therapeutics' Duchenne muscular dystrophy drug Elevidys, and the potential ...
The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback